This intricate interplay between HSP-90, HSP-70, and the SMURF2-HIF1α axis underscores the necessity of carefully modulated therapies that target these pathways, aiming to overcome cancer cells’ adaptive mechanisms to achieve more durable responses. This evidence concerns the gene HIF1A and cancer.